• Wei Wei, Bin Xu, Yan Wang, Chen Wu, Jingting Jiang, and Changping Wu.
• Department of Oncology Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
• Medicine (Baltimore). 2018 Jan 1; 97 (3): e9617e9617.

BackgroundThe prognostic significance of circulating soluble programmed death ligand-1 (sPD-L1) in patients with solid tumors remains unclear. We performed a meta-analysis to address this issue.MethodsSeveral electronic databases were searched from January 1970 to May 2017. The hazard ratios (HRs) and 95% confidence interval (95% CI) were calculated to determine the relationship between the level of soluble PD-L1 in peripheral blood and patient overall survival.ResultsA total of 1040 patients with solid tumors from 8 eligible studies were included in the present meta-analysis. The pooled HR suggested that a high level of soluble PD-L1 (sPD-L1) in peripheral blood was significantly correlated with a worse overall survival (HR = 2.26, 95% 1.83-2.80, Z = 7.51, P < .001).ConclusionThe present meta-analysis demonstrated that a high level of soluble PD-L1 in peripheral blood significantly predicts poor prognosis in patients with solid tumors, suggesting that high level of sPD-L1 may serve as a predictive biomarker for poor prognosis.Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

9 keywords...

hide…